Factors Affecting Growth Velocity during Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Idiopathic Central Precocious Puberty.

Cho,  Mun Sung; Suh,  Woo Suck; Park,  Sun Young; Choi,  Yun Jung; Lee,  Moon Hee; Cho,  Won Kyoung; Cho,  Kyoung Soon; Park,  So Hyun; Hahn,  Seung Hoon; Jung,  Min Ho; Suh,  Byung Kyu; Lee,  Byung Churl

doi:2012.17.2.106

Search: Ann Pediatr Endocrinol Metab Search

CLOSE

Ann Pediatr Endocrinol Metab > Volume 17(2); 2012 > Article

Original Article

Annals of Pediatric Endocrinology & Metabolism 2012;17(2): 106-112.

DOI: https://doi.org/10.6065/apem.2012.17.2.106

Factors Affecting Growth Velocity during Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Idiopathic Central Precocious Puberty.

Mun Sung Cho, Woo Suck Suh, Sun Young Park, Yun Jung Choi, Moon Hee Lee, Won Kyoung Cho, Kyoung Soon Cho, So Hyun Park, Seung Hoon Hahn, Min Ho Jung, Byung Kyu Suh, Byung Churl Lee

Department of Pediatrics, The Catholic University of Korea School of Medicine, Seoul, Korea. jmhpe@catholic.ac.kr

Abstract

PURPOSE
In some girls with central precocious puberty (CPP), growth velocity (GV) decreases below the age-appropriate normal range during gonadotropin-releasing hormone agonist (GnRHa) treatment. The purpose of this study was to investigate clinical and laboratory factors related to changes in GV during GnRHa treatment in girls with CPP. METHODS: We analyzed clinical and laboratory data of 49 girls (aged 7.8+/-0.5 years) with idiopathic CPP who were treated with GnRHa. GV, height standard deviation score (SDS), hormonal parameters, pubertal stage, chronological age and bone age (BA) were evaluated.
RESULTS
GV during the first year of GnRHa treatment was 5.9+/-1.0 cm/yr and decreased significantly to 5.4+/-1.1 cm/yr during the second year of treatment (P = 0.005). GV during the third year (5.0+/-1.0 cm/yr) was not different from GV during the second year. During the second year of treatment, 8.2% and 36.7% of the girls had a GV < 4 cm/yr and < 5 cm/yr, respectively. Girls with relatively low GV during the second year of treatment (< 5 cm/yr) showed higher risk of advanced BA (> or = 11 yr) at 1 year (55.6% vs. 19.4%; odds ratio [OR], 5.2; P = 0.022). In multivariate logistic regression analysis, more advanced BA at 1 year (OR, 6.1; 95% confidence interval [CI], 1.57-23.87) and lower height SDS for BA at 1 year (OR, 0.24; 95% CI, 0.06-0.94) were associated with relatively decreased GV (< 5 cm/yr) during the second year of GnRHa treatment.
CONCLUSION
GV during and after the second year of GnRHa treatment in girls with idiopathic CPP remains within the normal prepubertal range, and relatively low GV during GnRHa treatment is associated with more advanced BA and lower height SDS for BA.

Keywords: Puberty, precocious;Gonadotropin-releasing hormone;Growth

TOOLS

PDF Links
Full text via DOI
Download Citation

Share :

METRICS

0 Crossref
4,312 View
37 Download

Related articles in APEM

Effectiveness of the triptorelin stimulation test compared with the classic gonadotropin-releasing hormone stimulation test in diagnosing central precocious puberty in girls2024 April;29(2)

Effect of gonadotropin-releasing hormone agonist treatment on near final height in girls with central precocious puberty and early puberty2023 March;28(1)

Commentary on "Effect of gonadotropin-releasing hormone agonist treatment on near final height in girls with central precocious puberty and early puberty"2023 March;28(1)

Comparison of the effect of gonadotropin-releasing hormone agonist dosage in girls with central precocious puberty2023 December;28(4)

Commentary on "Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty"2021 December;26(4)

Editorial Office: 501-107, 30 Seocho-daero 74-gil, Seocho-gu, Seoul 06622, Republic of Korea
Tel: +82-2-3471-4268 Fax: +82-2-3471-4269 E-mail: editor@e-apem.org